A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy.
Phase of Trial: Phase II
Latest Information Update: 23 Sep 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 14 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2009 New trial record